Alivus Life Sciences Limited (NSE:ALIVUS)

India flag India · Delayed Price · Currency is INR
1,004.50
-40.45 (-3.87%)
Apr 28, 2026, 3:29 PM IST
-3.07%
Market Cap 123.68B
Revenue (ttm) 25.12B
Net Income (ttm) 5.44B
Shares Out 122.74M
EPS (ttm) 44.23
PE Ratio 22.78
Forward PE 20.38
Dividend 5.00 (0.48%)
Ex-Dividend Date Sep 1, 2025
Volume 198,165
Average Volume 106,961
Open 1,044.95
Previous Close 1,044.95
Day's Range 1,001.35 - 1,059.80
52-Week Range 819.00 - 1,225.10
Beta 0.01
RSI 46.50
Earnings Date Apr 30, 2026

About Alivus Life Sciences

Alivus Life Sciences Limited develops, manufactures, and markets active pharmaceutical ingredients in India, Japan, Europe, North and Latin America, and internationally. It offers various APIs, such as olmesartan, telmisartan, solifenacin, sitagliptin, zonisamide, rosuvastatin, amiodarone, ezetimibe, lithium carbonate, oxcarbazepine, mirabegron, atovaquone, etoricoxib, remogliflozin, cabozantinib, and palbociclib for various therapeutic areas, including cardiovascular disease, central nervous system disorders, diabetes, gastrointestinal health,... [Read more]

Sector Healthcare
Founded 2001
Employees 2,203
Stock Exchange National Stock Exchange of India
Ticker Symbol ALIVUS
Full Company Profile

Financial Performance

In fiscal year 2025, Alivus Life Sciences's revenue was 23.87 billion, an increase of 4.54% compared to the previous year's 22.83 billion. Earnings were 4.86 billion, an increase of 3.13%.

Financial Statements

News

There is no news available yet.